Kailyn Rigby, MD
Family Medicine · Philadelphia, PANPI 1336705870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,582 and has fallen 89.1% since, to $172 in 2025.
Across 106 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$498
- Novo Nordisk$353
- AbbVie$296
- Lilly USA, LLC$268
- AstraZeneca$221
- Pfizer$128
- plus $488 from 10 others
What the payments were for
- Food & beverage$2,251100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 26 | $498 |
| Novo Nordisk | 18 | $353 |
| AbbVie | 19 | $296 |
| Lilly USA, LLC | 12 | $268 |
| AstraZeneca | 9 | $221 |
| Pfizer | 7 | $128 |
| Astellas Pharma US Inc | 1 | $118 |
| Johnson & Johnson | 1 | $98 |
| Amgen | 3 | $65 |
| Exact Sciences | 2 | $49 |
| Abbott | 2 | $44 |
| Merck | 2 | $34 |
| Gilead | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Bayer | 1 | $14 |
How this compares
$2,251 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 31 | $34,704 |
| JardianceEmpagliflozin | 23 | $33,039 |
| FarxigaDapagliflozin Propanediol | 28 | $26,410 |
| EliquisApixaban | 21 | $17,686 |
| MounjaroTirzepatide | 17 | $17,686 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,780 |
| XareltoRivaroxaban | 12 | $9,152 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,967 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 142 | $4,689 |
| Atorvastatin Calcium | 198 | $2,749 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,848 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $1,577 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,330 |
| Duloxetine Hcl | 39 | $1,117 |
| Pantoprazole Sodium | 67 | $1,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $268 | $52,39048 claims |
| Boehringer IngelheimJardiance | $22 | $33,03923 claims |
| AstraZenecaFarxiga | $221 | $26,41028 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $498 | $20,74740 claims |
| PfizerEliquis | $128 | $17,68621 claims |
| Johnson & JohnsonXarelto | $98 | $9,15212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Glenn RosenPhiladelphia$61K
- Jessica DefflerPhiladelphia$56K
- Casey LaffertyPhiladelphia$55K
- Margot SavoyPhiladelphia$31K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.